8281. Cardiac Tamponade as an Initial Manifestation of Infective Endocarditis With Rupture of the Aortic Wall.
作者: Juan Lacalzada-Almeida.;María Manuela Izquierdo-Gómez.;Guadalupe Sauchelli.;Belén Marí-López.;Javier García-Niebla.;Ignacio Laynez-Cerdeña.;Marta Martín-Cabeza.
来源: Circ Cardiovasc Imaging. 2020年13卷1期e009860页 8283. First-in-Human Experience With Peritoneal Direct Sodium Removal Using a Zero-Sodium Solution: A New Candidate Therapy for Volume Overload.
作者: Veena S Rao.;Jeffrey M Turner.;Matthew Griffin.;Devin Mahoney.;Jennifer Asher.;Sangchoon Jeon.;Peter S Yoo.;Nabil Boutagy.;Attila Feher.;Albert Sinusas.;F Perry Wilson.;Fredric Finkelstein.;Jeffrey M Testani.
来源: Circulation. 2020年141卷13期1043-1053页
Loop diuretics have well-described toxicities, and loss of response to these agents is common. Alternative strategies are needed for the maintenance of euvolemia in heart failure (HF). Nonrenal removal of sodium directly across the peritoneal membrane (direct sodium removal [DSR]) with a sodium-free osmotic solution should result in extraction of large quantities of sodium with limited off-target solute removal.
8284. OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B).
作者: D Ian Paterson.;George Wells.;Fernanda Erthal.;Lisa Mielniczuk.;Eileen O'Meara.;James White.;Kim A Connelly.;Juhani Knuuti.;Miroslaw Radja.;Mika Laine.;Benjamin J W Chow.;Riina Kandolin.;Li Chen.;Alexander Dick.;Carole Dennie.;Linda Garrard.;Justin Ezekowitz.;Rob Beanlands.;Kwan-Leung Chan.; .
来源: Circulation. 2020年141卷10期818-827页
Cardiac magnetic resonance (CMR) is a recommended imaging test for patients with heart failure (HF); however, there is a lack of evidence showing incremental benefit over transthoracic echocardiography. Our primary hypothesis was that routine use of CMR will yield more specific diagnoses in nonischemic HF. Our secondary hypothesis was that routine use of CMR will improve patient outcomes.
8285. Pulmonary Artery Sarcoma: An Unusual Cause of Acquired Supravalvular Pulmonary Stenosis.
作者: Angkawipa Trongtorsak.;Monravee Tumkosit.;Poonchavist Chantranuwatana.;Aekarach Ariyachaipanich.;Pairoj Chattranukulchai.;Smonporn Boonyaratavej.;Sarinya Puwanant.
来源: Circ Cardiovasc Imaging. 2020年13卷1期e009932页 8286. Postoperative Echocardiographic Appearance of the Mitral Valve After Nonresectional Leaflet Remodeling Repair Mimicking Thrombus.
作者: Jordan P Bloom.;Alexander D Shapeton.;Ravi Rasalingam.;Marco A Zenati.
来源: Circ Cardiovasc Imaging. 2020年13卷1期e009853页 8287. Cardiac Calcified Amorphous Tumor as a Rare Cause of Ischemic Stroke: Clinical Case.
作者: Benedetta Formelli.;Antonio Farina.;Francesca Pescini.;Vanessa Palumbo.;Maria Grazia D'Alfonso.;Andrea Oddo.;Fabio Mori.;Anna Poggesi.
来源: Circ Cardiovasc Imaging. 2020年13卷1期e009623页 8288. Orai1 Channel Inhibition Preserves Left Ventricular Systolic Function and Normal Ca2+ Handling After Pressure Overload.
作者: Fiona Bartoli.;Marc A Bailey.;Baptiste Rode.;Philippe Mateo.;Fabrice Antigny.;Kaveen Bedouet.;Pascale Gerbaud.;Rajendra Gosain.;Jeffrey Plante.;Katherine Norman.;Susana Gomez.;Florence Lefebvre.;Catherine Rucker-Martin.;Justin F X Ainscough.;Mark T Kearney.;Alexander-Francisco Bruns.;Jian Shi.;Hollie L Appleby.;Richard S Young.;Heba M Shawer.;Marjolaine Debant.;Ana-Maria Gomez.;David J Beech.;Richard Foster.;Jean-Pierre Benitah.;Jessica Sabourin.
来源: Circulation. 2020年141卷3期199-216页
Orai1 is a critical ion channel subunit, best recognized as a mediator of store-operated Ca2+ entry (SOCE) in nonexcitable cells. SOCE has recently emerged as a key contributor of cardiac hypertrophy and heart failure but the relevance of Orai1 is still unclear.
8289. Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke.
作者: Shreyansh Shah.;Li Liang.;Andrzej Kosinski.;Adrian F Hernandez.;Lee H Schwamm.;Eric E Smith.;Gregg C Fonarow.;Deepak L Bhatt.;Wuwei Feng.;Eric D Peterson.;Ying Xian.
来源: Circ Cardiovasc Qual Outcomes. 2020年13卷1期e006031页
Background Guidelines recommend against the use of intravenous tPA (tissue-type plasminogen activator; IV tPA) in acute ischemic stroke patients with prior ischemic stroke within 3 months. However, there are limited data on the safety of IV tPA in this population. Methods and Results A retrospective observational study of patients ≥66 years of age linked to Medicare claims and treated with IV tPA at Get With The Guidelines-Stroke hospitals (February 2009 to December 2015). We identified 293 patients treated with IV tPA who had a prior ischemic stroke within 3 months and 30 655 with no history of stroke. Patients with prior stroke had a higher stroke severity (median National Institutes of Health Stroke Scale, 11 [6-19] versus 11 [6-18]; absolute standardized difference, 11.2%) and a higher prevalence of cardiovascular comorbidities. Patients with prior stroke had a higher unadjusted risk for symptomatic intracranial hemorrhage (7.7% versus 4.8%) and in-hospital mortality (12.6% versus 8.9%), but these differences were not statistically significant after adjustment. When stratified by prespecified time epochs, the elevated risk for symptomatic intracranial hemorrhage was seen only within the first 14 days (16.3% versus 4.8%; adjusted odds ratio [aOR], 3.7 [95% CI, 1.62-8.43]) but not in other epochs (2.1% versus 4.8%; aOR, 0.38 [95% CI, 0.05-2.79] for 15-30 days and 7.4% versus 4.8%; aOR, 1.36 [95% CI, 0.77-2.40] for 31-90 days). In addition, patients with prior stroke were significantly more likely to have a combined outcome of in-hospital mortality or discharge to hospice (25.9% versus 17.0%; aOR, 1.70 [95% CI, 1.21-2.38]), less likely to be discharged to home (28.3% versus 32.3%; aOR, 0.72 [95% CI, 0.54-0.98]), or to have good functional outcomes at discharge (modified Rankin Scale, 0-1; 11.3% versus 20.0%; aOR, 0.46 [95% CI, 0.24-0.89]). Conclusions Stroke providers need to continue to be vigilant about the safety of IV tPA in patients with prior stroke, particularly those with an event in the previous 14 days.
8290. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association.
作者: Robb D Kociol.;Leslie T Cooper.;James C Fang.;Javid J Moslehi.;Peter S Pang.;Marwa A Sabe.;Ravi V Shah.;Daniel B Sims.;Gaetano Thiene.;Orly Vardeny.; .
来源: Circulation. 2020年141卷6期e69-e92页
Fulminant myocarditis (FM) is an uncommon syndrome characterized by sudden and severe diffuse cardiac inflammation often leading to death resulting from cardiogenic shock, ventricular arrhythmias, or multiorgan system failure. Historically, FM was almost exclusively diagnosed at autopsy. By definition, all patients with FM will need some form of inotropic or mechanical circulatory support to maintain end-organ perfusion until transplantation or recovery. Specific subtypes of FM may respond to immunomodulatory therapy in addition to guideline-directed medical care. Despite the increasing availability of circulatory support, orthotopic heart transplantation, and disease-specific treatments, patients with FM experience significant morbidity and mortality as a result of a delay in diagnosis and initiation of circulatory support and lack of appropriately trained specialists to manage the condition. This scientific statement outlines the resources necessary to manage the spectrum of FM, including extracorporeal life support, percutaneous and durable ventricular assist devices, transplantation capabilities, and specialists in advanced heart failure, cardiothoracic surgery, cardiac pathology, immunology, and infectious disease. Education of frontline providers who are most likely to encounter FM first is essential to increase timely access to appropriately resourced facilities, to prevent multiorgan system failure, and to tailor disease-specific therapy as early as possible in the disease process.
8291. SNO-MLP (S-Nitrosylation of Muscle LIM Protein) Facilitates Myocardial Hypertrophy Through TLR3 (Toll-Like Receptor 3)-Mediated RIP3 (Receptor-Interacting Protein Kinase 3) and NLRP3 (NOD-Like Receptor Pyrin Domain Containing 3) Inflammasome Activation.
作者: Xin Tang.;Lihong Pan.;Shuang Zhao.;Feiyue Dai.;Menglin Chao.;Hong Jiang.;Xuesong Li.;Zhe Lin.;Zhengrong Huang.;Guoliang Meng.;Chun Wang.;Chan Chen.;Jin Liu.;Xin Wang.;Albert Ferro.;Hong Wang.;Hongshan Chen.;Yuanqing Gao.;Qiulun Lu.;Liping Xie.;Yi Han.;Yong Ji.
来源: Circulation. 2020年141卷12期984-1000页
S-nitrosylation (SNO), a prototypic redox-based posttranslational modification, is involved in the pathogenesis of cardiovascular disease. The aim of this study was to determine the role of SNO of MLP (muscle LIM protein) in myocardial hypertrophy, as well as the mechanism by which SNO-MLP modulates hypertrophic growth in response to pressure overload.
8292. Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort.
作者: Claire E Raphael.;Véronique L Roger.;Yader Sandoval.;Mandeep Singh.;Malcolm Bell.;Amir Lerman.;Charanjit S Rihal.;Bernard J Gersh.;Bradley Lewis.;Ryan J Lennon.;Allan S Jaffe.;Rajiv Gulati.
来源: Circulation. 2020年141卷6期454-463页
Type 2 myocardial infarction (T2MI) occurs because of an acute imbalance in myocardial oxygen supply and demand in the absence of atherothrombosis. Despite being frequently encountered in clinical practice, the population-based incidence and trends remain unknown, and the long-term outcomes are incompletely characterized.
8293. Long-Distance Skiing and Incidence of Hypertension: A Cohort Study of 206 889 Participants in a Long-Distance Cross-Country Skiing Event.
作者: Kasper Andersen.;Ulf Hållmarker.;Stefan James.;Johan Sundström.
来源: Circulation. 2020年141卷9期743-750页
Hypertension is the leading risk factor for death worldwide, and high levels of physical activity are associated with a lower incidence of hypertension. The associations of excessive levels of exercise and incidence of hypertension are less well known. We aim to compare the incidence of hypertension among 206 889 participants in a long-distance cross-country skiing event and 505 542 people randomly sampled from the general population (matched to the skiers on age, sex, and place of residence).
8294. Genome-Wide Polygenic Score and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
作者: Connor A Emdin.;Pallav Bhatnagar.;Minxian Wang.;Sreekumar G Pillai.;Lin Li.;Hui-Rong Qian.;Jeffrey S Riesmeyer.;A Michael Lincoff.;Stephen J Nicholls.;Steven E Nissen.;Giacomo Ruotolo.;Sekar Kathiresan.;Amit V Khera.
来源: Circ Genom Precis Med. 2020年13卷1期e002767页
Genome-wide polygenic scores (GPSs) integrate information from many common DNA variants into a single measure of inherited susceptibility, and can identify individuals who are at substantially elevated risk of developing important common diseases., For coronary artery disease, about 8% of the population can be identified who are at triple the normal risk based on genetic variation alone. Among these high polygenic score individuals, adherence to a healthy lifestyle or use of statins may offset increased inherited risk.,
8295. Improved Survival With Extracorporeal Cardiopulmonary Resuscitation Despite Progressive Metabolic Derangement Associated With Prolonged Resuscitation.
作者: Jason A Bartos.;Brian Grunau.;Claire Carlson.;Sue Duval.;Adrian Ripeckyj.;Rajat Kalra.;Ganesh Raveendran.;Ranjit John.;Marc Conterato.;Ralph J Frascone.;Alexander Trembley.;Tom P Aufderheide.;Demetris Yannopoulos.
来源: Circulation. 2020年141卷11期877-886页
The likelihood of neurologically favorable survival declines with prolonged resuscitation. However, the ability of extracorporeal cardiopulmonary resuscitation (ECPR) to modulate this decline is unknown. Our aim was to examine the effects of resuscitation duration on survival and metabolic profile in patients who undergo ECPR for refractory ventricular fibrillation/ventricular tachycardia out-of-hospital cardiac arrest.
8296. Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension: Hemodynamic Phenotyping and Histomorphometric Assessment.
作者: Christian Gerges.;Mario Gerges.;Richard Friewald.;Pierre Fesler.;Peter Dorfmüller.;Smriti Sharma.;Kristof Karlocai.;Nika Skoro-Sajer.;Johannes Jakowitsch.;Bernhard Moser.;Shahrokh Taghavi.;Walter Klepetko.;Irene M Lang.
来源: Circulation. 2020年141卷5期376-386页
Pulmonary endarterectomy (PEA) is the gold standard treatment for patients with operable chronic thromboembolic pulmonary hypertension. However, persistent pulmonary hypertension (PH) after PEA remains a major determinant of poor prognosis. A concomitant small-vessel arteriopathy in addition to major pulmonary artery obstruction has been suggested to play an important role in the development of persistent PH and survival after PEA. One of the greatest unmet needs in the current preoperative evaluation is to assess the presence and severity of small-vessel arteriopathy. Using the pulmonary artery occlusion technique, we sought to assess the presence and degree of small-vessel disease in patients with chronic thromboembolic pulmonary hypertension undergoing PEA to predict postoperative outcome before surgery.
8297. Unusual Case of Acquired Hypoxemia Following Left Ventricular Assist Device Implantation.
作者: Suneet N Purohit.;Paul J Lee.;Aaron L Strobel.;Aken A Desai.;Maria T Marsala.;Todd M Bull.;Andreas Brieke.;Daniel Vargas.;Joseph D Kay.;Natasha L Altman.
来源: Circ Heart Fail. 2020年13卷1期e006394页 8298. DP1 Activation Reverses Age-Related Hypertension Via NEDD4L-Mediated T-Bet Degradation in T Cells.
作者: Deping Kong.;Qiangyou Wan.;Juanjuan Li.;Shengkai Zuo.;Guizhu Liu.;Qian Liu.;Chenchen Wang.;Peiyuan Bai.;Sheng-Zhong Duan.;Bin Zhou.;Fotini Gounari.;Ankang Lyu.;Michael Lazarus.;Richard M Breyer.;Ying Yu.
来源: Circulation. 2020年141卷8期655-666页
Blood pressure often rises with aging, but exact mechanisms are still not completely understood. With aging, the level of proinflammatory cytokines increases in T lymphocytes. Prostaglandin D2, a proresolution mediator, suppresses Type 1 T helper (Th1) cytokines through D-prostanoid receptor 1 (DP1). In this study, we aimed to investigate the role of the prostaglandin D2/DP1 axis in T cells on age-related hypertension.
8299. Doubly Robust Estimation of Causal Effect: Upping the Odds of Getting the Right Answers.
Propensity score-based methods or multiple regressions of the outcome are often used for confounding adjustment in analysis of observational studies. In either approach, a model is needed: A model describing the relationship between the treatment assignment and covariates in the propensity score-based method or a model for the outcome and covariates in the multiple regressions. The 2 models are usually unknown to the investigators and must be estimated. The correct model specification, therefore, is essential for the validity of the final causal estimate. We describe in this article a doubly robust estimator which combines both models propitiously to offer analysts 2 chances for obtaining a valid causal estimate and demonstrate its use through a data set from the Lindner Center Study.
|